Dr. Reddy's Custom Pharmaceutical Services (CPS) Business Expands Its Manufacturing Operations in Mirfield, UK

Mon Oct 8, 2012 8:54am EDT

* Reuters is not responsible for the content in this press release.

Dr. Reddy's Custom Pharmaceutical Services (CPS) Business Expands Its Manufacturing Operations in Mirfield, UK

The Custom Pharmaceutical Services (CPS) business of Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced expansion in the areas of activated mPEG manufacturing and in the development and manufacture of NCE (New Chemical Entities) APIs for use in pre-clinical through to commercial development at its manufacturing facility in Mirfield, UK.

The expansion puts Dr. Reddy's at the forefront of activated mPEG manufacturing and will enable manufacture of its PEGtechTM range at commercial metric tonne scale quantities and beyond in a fully cGMP environment. Equipped with state-of-the-art DCS computer control systems, the plant operates with a very high level of control and has been designed with the latest manufacturing compliance standards in mind.

Commenting on the development, Dr. R. Ananthanarayanan, President-Pharmaceutical Services and Active Ingredients business, Dr. Reddy’s said, “This expansion builds on our commitment to expand operations in UK and provide a superior network of cGMP manufacturing to support our global customer base. PEGylation is one area where we felt the need for expanding our capabilities. We have invested in multiple technology areas and the expansion will add significant value in the areas of mPEGs and cGMP API manufacturing.”

Dr. Reddy’s has eight API manufacturing facilities (Six FDA-approved plants in India, One FDA-approved plant in Mexico and One FDA-approved plant in Mirfield, UK) worldwide which helps the CPS business to provide its customers with multiple site options.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: www.drreddys.com

Dr. Reddy's Laboratories Ltd.
Investors and Financial Analysts:
Kedar Upadhye
+91-40-66834297
kedaru@drreddys.com
or
Saunak Savla
+91-40-49002135
saunaks@drreddys.com
or
Milan Kalawadia (USA)
+1 908-203-4931
mkalawadia@drreddys.com
or
Media:
S Rajan
+91-40-49002445
rajans@drreddys.com
or
Business Development:
Mark Pearson
mpearson2@drreddys.com
or
Christian Jones
cjones@drreddys.com

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.